title: Synoviorthesis with radioactive Yttrium in haemophilia: Israel experience.
abstract: Radioactive Yttrium-90 (90Y) was injected into 163 joints. Of these patients 115 were persons with haemophilia and they suffered from recurrent haemarthroses. The median age at the time of the initial exposure to 90Y was between 11 and 15 years and the median follow-up period 11 years. Over 80% of the patients with haemophilia reported a decrease in the number of haemarthroses and 15% stopped bleeding altogether in the treated articulation. The safety of this modality of management has been reported and hence the patients age should not be regarded as a criteria.
authors.affiliation: Israel National Haemophilia Centre, Tel Hashomer Hospital, Israel. heim2@hotmail.com
authors.forename: M
authors.initials: M
authors.lastname: Heim
authors.forename: E
authors.initials: E
authors.lastname: Goshen
authors.forename: Y
authors.initials: Y
authors.lastname: Amit
authors.forename: U
authors.initials: U
authors.lastname: Martinowitz
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005500:Follow-Up Studies; D006395:Hemarthrosis / Q000150:complications / Q000188:drug therapy / Q000209:etiology; D006467:Hemophilia A / Q000150:complications* / Q000473:pathology / Q000628:therapy; D006801:Humans; D007223:Infant; D007270:Injections, Intra-Articular; D007557:Israel; D008875:Middle Aged; D012189:Retrospective Studies; D013585:Synovitis / Q000209:etiology / Q000473:pathology / Q000532:radiotherapy*; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D015021:Yttrium Radioisotopes